Primary malignant tumors of liver: the results of observation of patients been registered in Sverdlovsk Region in 2016
https://doi.org/10.18027/2224-5057-2018-8-1-61-65
Abstract
305 patients with primary malignant tumors of liver and bile-ducts (C22 according to ICD) were registered in Sverdlovsk Region in 2016. Only 123 of them (40.3%) got consultation in Sverdlovsk Regional Oncology Dispensary. Autopsy was performed in 251 cases (91.9% of deceased patients). On the one hand the exceeding of mortality over morbidity point out the failure of cases registration, on the other hand patients with another type of tumors were identified among the registered ones (4.3%). The majority of liver primary tumors are presented by hepatocellular carcinoma (81.6%). It is usually diagnosed at the age of 60 and older (78.2%) and stage IV (47.9%). Specialized anticancer treatment is not enough provided (just in 18.4% cases). It gives an opportunity to increase the median survival up to 18 months comparing with 1.5 months on best supportive care.
About the Authors
V. V. Petkau
State Budgetary Institution of Healthcare of Sverdlovsk Region “Sverdlovsk Regional Oncology Dispensary”;
Federal State Budgetary Institution of Higher Professional Education “Urals State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
MD, PhD Med, Head of the Outpatient Department
Associate professor of the Department of Oncology and Medical Radiology
L. A. Shabunina
State Budgetary Institution of Healthcare of Sverdlovsk Region “Sverdlovsk Regional Oncology Dispensary”
Russian Federation
Head of the Organizational and Methodical Department
Russian Federation
Head of the Organizational and Methodical Department
E. N. Bessonova
Federal State Budgetary Institution of Higher Professional Education “Urals State Medical University” of the Ministry of Healthcare of the Russian Federation;
Sverdlovsk Regional Hepatological Center on the base of State Budgetary Health Care Institution “Sverdlovsk Regional Hospital № 1”
Russian Federation
Russian Federation
MD, DSc Med, Head of the Sverdlovsk Regional Hepatological Center on the base
Associate Professor of the Department of Internal Medicine of Advanced Training and Retraining Faculty
References
1. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017. Vol. 3 (12). P. 1683–1691.
2. Forman D., Bray F., Brewster D.H. et al. Cancer incidence in five continents. Volume X. International Agency for Research on Cancer. Sci. Publ. №164. Lyon, France, 2014. 1365 p.
3. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015. Vol. 136. P. E359–E386.
4. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTs” Minzdrava Rossii, 2016. 236 p. (In Russ.)].
5. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2015 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2016. 236 с. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2015 godu. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTs” Minzdrava Rossii, 2016. 236 p. (In Russ.)].
6. Мерабишвили М.Н., Мерабишвили Э.Н., Чепик О.Ф. Эпидемиология рака печени. Эпидемиология, смертность, динамика гистологической структуры // Сибирский онкологический журнал. 2015. №2. С. 5–14. [Merabishvili M.N., Merabishvili E.N., Chepik O. F. Epidemiologiya raka pecheni. Epidemiologiya, smertnost’, dinamika gistologicheskoy struktury. Sibirskiy onkologicheskiy zhurnal. 2015. No. 2. P. 5-14. (In Russ.)].
7. Polednak A.P. Using cancer registries to assess the accuracy of primary liver or intrahepatic bile duct cancer as the underlying cause of death, 1999-2010. J. Registry Manag. 2013. Vol. 40 (4). P. 168–175.
8. Siegel R. et al. Cancer statistics, 2016. CA Cancer J. Clin. 2016. Vol. 66. P. 7-30.
9. Torre L.A., Bray F., Siegel R. L. et al. Global cancer statistics, 2012. CA. Cancer J. Clin. 2015. Vol. 65. P. 87-108.
10. Бредер В.В., Патютко Ю.И., Перегудова М.В. и др. Сравнительный анализ современных систем стадирования гепатоцеллюлярного рака – TNM/AJCC, CUPI, CLIP и BCLC в Российской онкологической практике. Опыт Российского онкологического научного центра им. Н.Н. Блохина // Злокачественные опухоли. 2016. №2. С. 28–36. [Breder V.V., Patyutko Yu. I., Peregudova M.V. et al. Sravnitel’nyy analiz sovremennykh sistem stadirovaniya gepatotsellyulyarnogo raka – TNM/AJCC, CUPI, CLIP i BCLC v Rossiyskoy onkologicheskoy praktike. Opyt Rossiyskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina. Zlokachestvennye opukholi. 2016. No. 2. P. 28-36. (In Russ.)].
11. Патютко Ю.И., Пылев А.Л., Сагайдак И.В. и др. Десятилетняя выживаемость больных злокачественными опухолями печени после хирургического лечения // Анналы хирургической гепатологии. 2010. Т. 15. №3. С. 39–47. [Patyutko Yu. I., Pylev A. L., Sagaydak I.V. et al. Desyatiletnyaya vyzhivaemost’ bol’nykh zlokachestvennymi opukholyami pecheni posle khirurgicheskogo lecheniya. Annaly khirurgicheskoy gepatologii. 2010. Vol. 15. No. 3. P. 39-47. (In Russ.)].
12. Вишневский В.А., Ефанов М. Г., Икрамов Р.З. и др. Опухоли печени: диагностика и хирургическое лечение // Доказательная гастроэнтерология. 2013. №2. С. 38–47. [Vishnevskiy V.A., Efanov M.G., Ikramov R.Z. et al. Opukholi pecheni: diagnostika i khirurgicheskoe lechenie. Dokazatel’naya gastroenterologiya. 2013. No. 2. P. 38-47. (In Russ.)].
13. Bruix J., Gores G. J., Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014. Vol. 63. P. 844-855.
14. Knox J. J., Cleary S.P., Dawson L.A. Localized and Systemic Approaches to Treating Hepatocellular Carcinoma. J. Clin. Oncol. 2015. Vol. 33. P. 1835–1844.
15. Бредер В.В., Лактионов К.К., Давыдов М.М. Лекарственное лечение гепатоцеллюлярного рака: практические вопросы и решения // Медицинский совет. 2017. №14. С. 11–23. [Breder V.V., Laktionov K.K., Davydov M.M. Lekarstvennoe lechenie gepatotsellyulyarnogo raka: prakticheskie voprosy i resheniya. Meditsinskiy sovet. 2017. No. 14. P. 11-23. (In Russ.)].
16. Wang S., Sun H., Xie Z. et al. Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983–2012. Oncotarget. 2016. Vol. 7. No. 37. P. 59820-59833.
17. Park J.W., Chen M., Colombo M. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver International. 2015. Vol. 35 (9). P. 2155-2166.
Review
For citations:
Petkau V.V., Shabunina L.A., Bessonova E.N. Primary malignant tumors of liver: the results of observation of patients been registered in Sverdlovsk Region in 2016. Malignant tumours. 2018;8(1):61-65. (In Russ.) https://doi.org/10.18027/2224-5057-2018-8-1-61-65
Views:
986
Email this article 